Crinetics Pharmaceuticals (CRNX) Common Equity (2017 - 2026)

Crinetics Pharmaceuticals' Common Equity history runs 10 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 2.12% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 2.12% increase from a year earlier, with the FY2025 full-year figure at $992.1 million, down 25.11% from the prior year.
• Common Equity climbed to $1.3 billion in Q1 2026 per CRNX's latest filing, from $992.1 million in the prior quarter.
• Across five years, Common Equity topped out at $1.3 billion in Q4 2024 and bottomed at $254.1 million in Q2 2023.
• The 5-year median for Common Equity is $830.8 million (2024), against an average of $741.9 million.
• Across the five-year window, Common Equity slumped 34.19% in 2023 and surged 226.92% in 2024, its largest moves.
• Year by year, Common Equity stood at $316.3 million in 2022, then soared by 70.43% to $539.1 million in 2023, then surged by 145.74% to $1.3 billion in 2024, then retreated by 25.11% to $992.1 million in 2025, then gained by 29.09% to $1.3 billion in 2026.
• Per Business Quant, the three latest CRNX Common Equity figures stand at $1.3 billion (Q1 2026), $992.1 million (Q4 2025), and $1.1 billion (Q3 2025).